Table 2.
Glioma grading: Summary of literature results.
| Study (n) | Group (n) | Mean rCBV | Mean PSR (%) | rCBV threshold (Sn%; Sp%) | PSR threshold (%) (Sn%; Sp%) | Comments | Level of evidenceb |
|---|---|---|---|---|---|---|---|
| Law 2003 (160) | HGG (120) | 5.18a (max) | NA | 2.97 (72.5; 87.5) | NA | Retrospective study, though comparatively large. Mean rCBV not reported; max rCBV values referred to. | 4 |
| LGG (40) | 2.14a (max) | NA | |||||
| Lev 2004 (30) | HGG (17) | 2.9a | 1.5 (97; 55) | NA | LGG rCBV lower (1.3) when oligodendroglioma excluded. | 4 | |
| LGG (13) | 1.5a | ||||||
| Hakyemez 2005 (33) | HGG (22) | 6.5a | NA | 2.00 (100; 90.9) | NA | Prospective study. Inclusion of anaplastic oligodendroglioma in HGG group and oligodendroglioma in LGG group is controversial. | 4 |
| LGG (11) | 1.69a | NA | |||||
| Boxerman 2006 (43) | Grade II (11) | 1.52a | NA | Not provided | NA | No significant difference between Grade III and Grade IV tumours found. | 4 |
| Grade III (9) | 2.84a | NA | |||||
| Grade IV (23) | 3.96a | NA | |||||
| Server 2011 (79) | HGG (61) | 6.6a | NA | 2.94 (98.4; 72.2) | NA | Prospective. Some patients on steroids. Inclusion of oligodendroglioma in LGG controversial. | 4 |
| LGG (18) | 2.42a | NA | |||||
| Aprile 2015 (49) | HGG (31) | 5.0 | 65.8a | 2.6 (77.7; 74.1) | 89 (94.4; 96.8) | Retrospective. Difference in rCBV between LGG and HGG not statistically significant (p > 0.05). | 4 |
| LGG (18) | 2.3 | 94.9a | |||||
| Smitha 2015 (64) | HGG (25) | 5.29a | 81.4a | Not provided | Prospective. All patients treatment naïve. | 4 | |
| LGG (39) | 2.60a | 94.8a | |||||
a
P < 0.05.
bSee Appendix A.
HGG: high-grade glioma; LGG: low-grade glioma; NA: not studied; PSR: percentage of signal intensity recovery; rCBV: relative cerebral blood volume; Sn: sensitivity; Sp: specificity; vs.: versus